

CYBO VanEck Bionic Engineering UCITS ETF



Fund Details

Base Currency	USD
Inception Date	02 December 2022
Domicile	Ireland
Net Assets	USD 6.4M
Shares Outstanding	290,000
Total Expense Ratio	0.55%
Product Structure	Physical (Full Replication)
UCITS Compliant	Yes
Rebalance Frequency	Quarterly
Distribution Frequency	None
Income Treatment	Reinvestment
Swiss Valor	--
ISA Eligibility	Yes
SIPP Available	Yes
Countries of Registration	AT, CH, DE, DK, ES, FI, FR, IE, IT, LU, NL, NO, PL, PT, SE, UK

Index Information

Index Provider	MarketVector Indexes GmbH
Index Type	Total Return Net
Currency	USD
Inception Date	06 Dec 2021
Rebalance Frequency	Quarterly
Bloomberg Ticker	MVBIONTR
Reuters Ticker	.MVBIONTR

Fund Data

Number of Holdings	25
Price/Earnings Ratio*	41.12
Price/Book Ratio*	4.47
Weighted Avg. MCap	USD 42.9B

* Last 12 Months

Country Breakdown

United States	78.71%
Switzerland	8.09%
Australia	4.57%
United Kingdom	3.07%
Italy	2.25%
Denmark	1.85%
Other/Cash	1.45%

Fund Description

31 March 2024

The VanEck Bionic Engineering UCITS ETF (CYBO) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS® Global Bionic Healthcare ESG Index.

The MVIS® The MVIS Global Bionic Healthcare ESG Index is a global index that tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, or prosthesis.

Performance History* (%)

Month End as of 31 Mar 2024	1 MO*	3 MO*	YTD*	1 YR	3 YR	5 YR	10 YR	ETF INCEPTION
ETF	6.30	7.21	7.21	3.90	--	--	--	7.38
MVBIONTR (Index)	6.34	7.35	7.35	4.33	-0.81	--	--	7.85

Past performance does not predict future returns.

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12 month performance to the most recent Quarter end for each of the last 5yrs where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for VanEck ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

Top 10 Holdings

EDWARDS LIFESCIENCES CORP	10.55%
DEXCOM INC	10.12%
MEDTRONIC PLC	9.94%
STRYKER CORP	9.83%
ZIMMER BIOMET HOLDINGS INC	7.14%
COCHLEAR LTD	4.57%
SONOVA HOLDING AG	4.39%
STRAUMANN HOLDING AG	3.70%
INSULET CORP	3.53%
INSPIRE MEDICAL SYSTEMS INC	3.19%
SUBTOTAL - TOP 10	66.96%
REMAINING HOLDINGS	32.88%
OTHER/CASH	0.16%
TOTAL	100.00%

For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com

CYBO

VanEck
Bionic Engineering UCITS ETF



Trading Information

31 March 2024

EXCHANGE	TRADING CURRENCY	ISIN	EXCHANGE TICKER	BLOOMBERG TICKER	REUTERS TICKER	SEDOL	IOPV SYMBOL
LONDON STOCK EXCHANGE	USD	IE0005TF9619	CYBO	CYBO LN	CYBO.L	BMTPNY4	CYBOUSIV
LONDON STOCK EXCHANGE	GBP	IE0005TF9619	CYBG	CYBG LN	VVCYBG.L	BMTPPH1	--
SIX Swiss Exchange CHF	CHF	IE0005TF9619	CYBO	CYBO SE	CYBO.S	BMTPLL5	--
BORSA ITALIANA	EUR	IE0005TF9619	CYBO	CYBO IM	CYBO.MI	BMTPPK4	CYBOUSIV

Key Risks

Liquidity Risk: It exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price or at all. This is a main risk factor of a Bionic ETF.

Equity Market Risk: The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in a Bionic ETF may lose money.

Industry or Sector Concentration Risk: The Fund's assets may be concentrated in one or more particular sectors or industries. A Bionic ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries.

For more information on risks, please see the "Risk Factors" section of the relevant Fund's prospectus, available on www.vaneck.com.

IMPORTANT INFORMATION

This is a marketing communication. VanEck does not directly distribute to retail investors. Please refer to the UCITS prospectus and to the Key Investor Information Document (KIID) before making any final investment decisions.

This information originates from VanEck Securities UK Limited (FRN: 1002854), an Appointed Representative of Sturgeon Ventures LLP (FRN: 452811), who is authorised and regulated by the Financial Conduct Authority in the UK. The information is intended only to provide general and preliminary information to FCA regulated firms such as Independent Financial Advisors (IFAs) and Wealth Managers. Retail clients should not rely on any of the information provided and should seek assistance from an IFA for all investment guidance and advice. VanEck Securities UK Limited and its associated and affiliated companies (together "VanEck") assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply.

VanEck Asset Management B.V., the management company of VanEck Bionic Engineering UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.

Investors must read the sales prospectus and key investor information before investing in a fund. These can be obtained free of charge at www.vaneck.com, from the local information agent Computershare Investor Services PLC or from the Management Company.

MVIS®Global Bionic Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH ("MarketVector"), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Bionic Engineering UCITS ETF (the "ETF") is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the ETF.

It is not possible to invest directly in an index.

All performance information is based on historical data and does not predict future returns.

Note: no guarantee can be provided that the fund will attain its objective. Investing is subject to risk, including the possible loss of principal.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

The IOPV is calculated by S&P Global Ltd.

© VanEck Securities UK Limited